Continued.
| No. | Age/sex/code | Histology | Sitea | Sizeb | Follow-up in months | CGH karyotypea | |
|---|---|---|---|---|---|---|---|
| Losses | Gains and high-level amplifications | ||||||
| 51 | 54/m PR10 | Malignant | Jejunum | 15 | Alive, 22 | 1p, 2, 7p, 11, 15, 18, 22 | 4q, 7q, 9p, 12q |
| 51b | PR11 | Metastases | Abdomen | 1p, 2, 4p, 11, 12p, 13, 15, 17p, 18, 22 | 5q, 7q, 8q, 9p, 21 | ||
| 51c | PR12 | Metastases | Abdomen | 1p, 2p, 13, 15, 18, 22 | 5q, 10p | ||
| 52 | 59/m PR13 | Malignant | Small intestine | 20 | DOD, 49 | 1p, 8, 13, 14, 15, 22 | 1q, 2q22–qter, 4p, 5p, 17, 20p |
| 52b | PR14 | Metastases | Abdomen | 1p, 3pter–q13, 4q, 8, 9pter–q21, 10, 13, 14, 15, 22 | 1q, 2q22–qter, 4p, 5p, 17, 20p | ||
| 52c | PR15 | Metastases | Abdomen | 1p, 3pter–q13, 4q, 8, 9pter–q21, 13, 14, 15, 22 | 1q, 2q22–qter, 5p, 17, 20p | ||
| 53 | 62/f PR16 | Malignant | Stomach | 15 | Alive, 60 | 6, 9, 12pter–q22, 14, 22 | 17 |
| 53b | PR17G5 | Metastases | Abdomen | Alive | 9, 14, 22 | 17q | |
| 53c | PR18 | Metastases | Abdomen | 9, 14, 22 | 4, 17q, 20 | ||
| 54 | 59/m PR19G3 | Malignant | Ileum | 12 | DOD, 14 | 13, 14q11–q12 | 5p |
| 54b | PR20 | Metastases | Liver | 12p, 14 | 5p, 8q | ||
| 55 | 38/f PR21 | Malignant | Jejunum | 10 | DOD, 59 | 1p, 11q14–qter, 13, 14, 15, 18, 22, X | 1q, 5p, 8 |
| 55b | PR22 | Metastases | Abdomen | 1p, 15, 18, 22q13 | 1q, X | ||
| 55c | PR23 | Metastases | Abdomen | 1p, 15, 18, 22q13 | 1q | ||
| 55d | PR24 | Metastases | Abdomen | 1p, 13, 15, 18, 22 | 1q | ||
| 56 | 52/f PR33 | Malignant | Small intestine | 10 | DOD, 12 | 1p, 14, 15 | 7, 8, 12q22–qter |
| 56b | PR34 | Metastases | Abdomen | 1p, 14, 15 | 7, 8, 12q22–qter | ||
| 57c | PR35 | Metastases | Abdomen | 1p, 14, 15 | 7, 8, 12q22–qter | ||
| 58 | 61/m PR36 | Malignant | Stomach | 25 | DOD, 19 | 1p, 11, 13, 14, 15 | 2q, 8q23–qter, 17q, X |
| 58b | PR37 | Metastases | Abdomen | 1p, 9 | 20 | ||
| 58c | PR38 | Metastases | Abdomen | 1p, 9 | 17q22–qter, 20 | ||
| 59 | 39/m PR39 | Malignant | Stomach | 20 | DOD, 14 | 4q27–q34, 9, 14, 22 | |
| 59b | PR40 | Metastases | Abdomen | 4q27–q34, 9, 14, 22 | |||
| 59c | 33/m PR42 | Metastases | Abdomen | 1p11–p32, 4, 9pter–q33, 14 | 20q13.2–qter | ||
| 60 | 41/f PR45 | Malignant | Stomach | 6 | Alive, 6 | 1p35–pter, 4, 9, 15, 22 | 5, 8p12–pter, 8q23–qter, 12q14–qter, 13, 18q |
| 60b | PR46 | Metastases | Abdomen | 1p35–pter, 4, 6q, 9, 14q11–q21, 15, 22 | 5, 8p12–pter, 8q23–qter, 12 (12q22–qter), 13, 18q, 20q | ||
| 60c | PR47 | Metastases | Abdomen | 1p35–pter, 4, 9, 10, 14, 15, 22 | 5p, 5q32–qter, 8p12–pter, 8q23–qter, 12 (12q22–qter), 13, 20q | ||
All metastases were intra-abdominal.
Maximum size in cm, high.
High-level amplifications are in bold; NED, no evidence of disease; NA, not available; DOD, died of disease.